CARM (CARISMA Therapeutics) Net Margin %: 98.82% (As of Sep. 2025)


What is CARISMA Therapeutics Net Margin %?

CARISMA Therapeutics CARM +1.25% Net Margin % is 98.82% as of Sep. 2025. The stock has 3 warning signs investors should review. Among 947 Biotechnology companies, CARISMA Therapeutics ranks better than 84.48% on this metric.

Net margin is calculated as Net Income divided by its Revenue. CARISMA Therapeutics's Net Income for the three months ended in Sep. 2025 was $44.72 Mil. CARISMA Therapeutics's Revenue for the three months ended in Sep. 2025 was $45.25 Mil. Therefore, CARISMA Therapeutics's net margin for the quarter that ended in Sep. 2025 was 98.82%.

The historical rank and industry rank for CARISMA Therapeutics's Net Margin % or its related term are showing as below:

CARM' s Net Margin % Range Over the Past 10 Years
Min: -622.6   Med: -582.34   Max: 15.28
Current: 15.28

CARM's Net Margin % is ranked better than
84.48% of 947 companies
in the Biotechnology industry
Industry Median: -89.56 vs CARM: 15.28

CARISMA Therapeutics  (OTCPK:CARM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

CARISMA Therapeutics Net Margin % Related Terms

CARISMA Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Net Margin % Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
0.00 0.00 -622.60 -582.34 -308.05

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -375.24 -482.75 -248.48 0.00 98.82

CARM vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, CARISMA Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's Net Margin % falls into.


CARISMA Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

CARISMA Therapeutics's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-60.477/19.632
=-308.05 %

CARISMA Therapeutics's Net Margin for the quarter that ended in Sep. 2025 is calculated as

Net Margin=Net Income (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=44.717/45.25
=98.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 98.82% mean?
CARISMA Therapeutics (CARM) has a Net Margin % of 98.82% as of Sep. 2025. Net margin is the ratio of total net income to net sales. View historical data on CARISMA Therapeutics and its competitors. According to the industry distribution chart, CARISMA Therapeutics ranks #147 out of 947 companies in the Biotechnology industry, placing it in the top 15.5%.
Is CARISMA Therapeutics' Net Margin % too high?
CARISMA Therapeutics' current Net Margin % is 98.82%. Based on the distribution chart, CARISMA Therapeutics ranks #147 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does CARISMA Therapeutics' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CARISMA Therapeutics ranks #147 out of 947 companies for Net Margin %. This places CARISMA Therapeutics in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current Net Margin % is 98.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current Net Margin % is 98.82%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current Net Margin % is 98.82% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.